RAB GTPase activating protein 1 likeGenealiases: HHL · TBC1D18
Q-omics provides the consensus-scored RABGAP1L profile across patient tissues and cancer cell-line models. RABGAP1L expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, RABGAP1L is differentially expressed in 14, with the highest sampling consensus in KICH. Additionally, RABGAP1L RNA expression shows 20,692 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRP, KICH, and UVM as cancer lineages where RABGAP1L shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RABGAP1L — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RABGAP1L survival associations across molecular data types. RABGAP1L RNA expression shows survival associations in the most cancer types (28), followed by mutation status (5) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RABGAP1L RNA expression–survival associations across cancer types. High RABGAP1L expression shows unfavorable associations in KIRP, but favorable associations in HNSC, MESO, KIRC, BRCA and SKCM. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for RABGAP1L RNA expression.
This table summarizes RABGAP1L tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for RABGAP1L. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RABGAP1L shows lower tumor expression in KICH, KIRC and LUAD and higher tumor expression in BLCA, STAD and LIHC. The KICH box plot shows higher RABGAP1L RNA expression in normal versus tumor tissue (log2 FC = −0.850, t-test p < 0.001).
This table shows molecular features associated with RABGAP1L in patient tissues and cancer cell lines. In patient samples, RABGAP1L shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, RABGAP1L RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in CNS and UPPER_AERODIGESTIVE_TRACT.
